Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05209620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

StatusRecruiting
PhasePhase 2
Started2021-12-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-04-18
Study Status, Oversight, IPDSharing v3
Primary completion date2024-12-21→2025-06-30
2023-05-17
Study Status v2
Re-verified, no change to tracked fields
2022-01-28
Not Yet Recruiting→Recruiting Study Identification, Study Status, Study Description, Conditions, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-02-01→2024-12-21
Completion date2027-02-01→2026-12-21
Start dateestimated 2022-02-01→confirmed 2021-12-21
Study sitesdetails revised at 1 of 1 site
Study title-8 characters
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Primary Central Nervous System Lymphoma
2022-01-22
Original filing
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety of orelabrutinib combined with pemetrexed in the treatment for patients with relapsed/refractory central nervous system lymphoma.
Trial Details
NCT Number NCT05209620
Lead Sponsor Henan Cancer Hospital
Conditions Central Nervous System Lymphoma
Enrollment 30 participants
Start Date 2021-12-21
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-21 (estimated)
Updated on ClinicalTrials.gov 2025-04-23